"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
lymphoma, hodgkin lymphona, diffuse large b cell lymphoma (dlbcl), raynaud phenomenon, nail dystrophy
Medha R. Cherabuddi , Vijayalakshmi Donthireddy
Cite this article as: Cherabuddi M R, Donthireddy V (August 17, 2022) Dystrophic Nails: An Unusual Clue to Recurrent Lymphoma. Cureus 14(8): e28098. doi:10.7759/cureus.28098
Nail changes are a well-known phenomenon in T-cell lymphoma but have not been reported as widely in B-cell lymphomas and Hodgkin lymphomas. We describe a patient with a history of diffuse large B-cell lymphoma in a background of nodular lymphocyte predominant Hodgkin lymphoma treated eight years prior who developed new nail changes that were noted on a routine surveillance visit. He had developed symptoms of painful fingertips that became white and required him to wear gloves even in warm weather, suggestive of Raynaud phenomenon. Due to a suspicion of a paraneoplastic phenomenon, a positron emission tomography-computed tomography was obtained, which showed fluorodeoxyglucose avid uptake involving the spleen and retroperitoneal, para-aortic, and right inguinal lymph nodes. Right inguinal lymph node biopsy was non-diagnostic and a splenectomy was performed. Pathology evaluation of the spleen revealed recurrent nodular lymphocyte-predominant Hodgkin lymphoma. Treatment was initiated with rituximab-based systemic therapy. The Beau lines grew out eventually with normal new nail growth and there was an improvement in Raynaud phenomenon after systemic treatment.
Dystrophic nail changes are a well-known phenomenon described in T-cell lymphomas. Nail changes including discoloration, crumbling, onycholysis, Beau lines, ridging, pitting, thinning, etc., have been described in T-cell lymphomas [1, 2]. Reports of nail changes in B-cell lymphomas and Hodgkin lymphomas are limited.
Beau lines are horizontal ridges and indentations that develop on nails. They are indicative of a systemic insult that disrupts nail growth when they appear on multiple nails, such as sickness or chemotherapy. Beau lines are known to appear secondary to Raynaud phenomenon [3, 4]. Raynaud phenomenon has been reported as a paraneoplastic phenomenon in malignancies [5].
We report a case of Raynaud phenomenon and appearance of Beau lines as an unusual clue to systemic lymphoma recurrence.
A 68-year-old man had initially presented eight years prior to the current evaluation with worsening reflux symptoms and weight loss. A computed tomography scan of the abdomen and pelvis showed adenopathy in the mesentery, upper abdomen, and retroperitoneum including moderate splenomegaly around 14 cm with numerous ill-defined splenic lesions suspicious for lymphoma. A peri-gastric lymph node excisional biopsy revealed areas of typical nodular lymphocyte predominant Hodgkin lymphoma admixed with areas of diffuse large B-cell lymphoma in a T-cell/histiocyte-rich background. He was treated with six cycles of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone and achieved complete remission.
His current presentation stemmed from his report at a routine surveillance visit of having developed new symptoms of painful fingertips that became white along with nail changes that appeared gradually over the preceding year. He reported needing to wear gloves even at room temperature to keep them warm. His nails revealed evidence of Beau lines with horizontal indentations (Figure 1). Autoimmune workup including Scl-70, RNA polymerase III, ENA Ro/La antibodies, creatine phosphokinase (CPK), aldolase and protein electrophoresis was unremarkable, therefore the development of new Raynaud phenomenon raised suspicion for a paraneoplastic phenomenon due to lymphoma recurrence. Fluorodeoxyglucose-positron emission tomography scan was obtained, which showed multiple enlarged para-aortic, retroperitoneal, and right inguinal nodes demonstrating intense hypermetabolism. Scattered areas of focal hypermetabolic lesion were seen throughout the axial and appendicular skeleton involving multiple sites including the proximal right femur, right humerus, multiple ribs, left shoulder, and L1 vertebral body, and two hypodense lesions in the spleen. A right inguinal lymph node biopsy was non-diagnostic. A splenectomy was performed after the completion of pre-splenectomy immunizations.
Pathologic evaluation of the spleen revealed recurrent nodular lymphocyte-predominant Hodgkin lymphoma (Figures 2, 3).
Nail changes occasionally are a window into the systemic health of the human body. Among the numerous nail changes that are reflective of systemic disease, Beau lines are well described. Beau lines are horizontal indentations and ridges that denote nail plate effects of systemic insults at the time of initial nail formation, such as severe systemic illness, trauma or toxin exposure such as chemotherapy [6]. Beau lines can also be reflective of vascular flow compromise to the tips of digits such as in Raynaud phenomena. Systemic responses to underlying neoplasms manifesting as paraneoplastic phenomena are well-reported, and Raynaud phenomena can result from underlying hematologic or solid organ malignancy [7, 8].
The pathophysiology of Raynaud phenomena is not well understood in the setting of malignancies. Impaired microvasculature, reduced production of vasodilators, and exaggerated response to vasoconstrictors have been postulated [9]. Such vasoconstrictive insult to the actively growing nail plate can cause changes in the deposition of nail matrix leading to Beau nails.
The new occurrence of Raynaud phenomenon or Beau lines should raise suspicion of a systemic process. In our patient, since he had a previous history of lymphoma, there was an immediate evaluation for evidence of disease recurrence. However, in a patient without a prior history of malignancy, a high index of suspicion for an evolving systemic disease is necessary to investigate secondary Raynaud phenomenon before embarking solely on symptomatic therapy.
Our patient was treated for recurrent nodular lymphocyte-predominant Hodgkin lymphoma with rituximab with a good response. The Beau lines grew out eventually with normal new nail growth by six months after treatment (Figure 4). There was an improvement in Raynaud phenomenon around six weeks after treatment.
In conclusion, the appearance of new dystrophic nail changes should raise suspicion of systemic disease. Beau lines can result from Raynaud phenomenon, which can be a paraneoplastic manifestation of lymphoma and an early sign of recurrent lymphoma.
Internal Medicine, Henry Ford Health System, Detroit, USA
Hematology/Oncology, Henry Ford Health System, Detroit, USA
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Cherabuddi M R, Donthireddy V (August 17, 2022) Dystrophic Nails: An Unusual Clue to Recurrent Lymphoma. Cureus 14(8): e28098. doi:10.7759/cureus.28098
Peer review began: August 01, 2022 Peer review concluded: August 15, 2022 Published: August 17, 2022
© Copyright 2022 Cherabuddi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.
This link will take you to a third party website that is not affiliated with Cureus, Inc. Please note that Cureus is not responsible for any content or activities contained within our partner or affiliate websites.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
High ratings should be reserved for work that is truly groundbreaking in its respective field. Anything above 5 should be considered above average. While all registered Cureus users can rate any published article, the opinion of domain experts is weighted appreciably more than that of non-specialists. An article’s SIQ™ will appear alongside the article after being rated twice and is recalculated with each additional rating.
Visit our SIQ™ page to find out more.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
Already have an account? Sign in.
Please note that by doing so you agree to be added to our monthly email newsletter distribution list.
By joining Cureus, you agree to our Privacy Policy and Terms of Use.